Predictive factors of sorafenib in the treatment of metastatic renal cell carcinoma

VernacularTitle:索拉非尼治疗转移性肾癌的疗效预测因素分析
Author: Xinan SHENG ; Zhihong CHI ; Hongyun LIAN ; Xiangqing YUAN ; Lu SI ; Chuanliang CUI ; Jun GUO
Publication Type:Journal Article
Keywords: Carcinoma,renal cell; Predictive factors; Sorafenib
From: Chinese Journal of Urology 2009;30(1):25-27
CountryChina
Language:Chinese
Abstract: Objective To analyze the effect and related factors of sorafenib in the treatment of metastatic renal cell carcinoma(MRCC), and identify the potential predictive factors of sorafenib re-sponse. Methods The data of 51 MRCC patients who received sorafenib therapy, with or without combination with interferon or chemotherapy were retrospectively reviewed. After two cycles of treat-ment, patients were evaluated for progression or response. Pearson Chi-square test and Logistic re-gression test were performed respectively as univariate and multivariate analyses of sorafenib response. Results The overall objective response rate was 29.4%(95% confidence interval 16.9% to 41.9%, with 1(2.0%) complete response and 14(27.4%) partial responses. Twenty-nine(56.9%) had stable disease, and 7 (13.7%) had progression disease (PD). Significant independent predictive factors asso-ciated with good response in multivariate analysis were lung metastasis only(P=0.021, HR=5.127). Conclusions Sorafenib is effective in MRCC patients. Lung metastasis only is predictive factor in mul-tivariate analysis for sorafenib response.